Applied Genetics Technologies Corporation

AGTC is a clinical-stage biotechnology company developing gene therapies to treat patients with rare genetic disorders. Our most advanced therapeutic programs aim to restore visual function and address the needs of patients with rare blinding conditions. AGTC's lead product candidates are designed to treat inherited orphan eye diseases, which are caused by single-gene mutations that significantly impact visual function and currently lack effective treatment options.